Pancreatic Cancer Research

ResearcherShanxi Medical UniversityActive in the last 2 years

Chengfeng Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2931-9085; OpenAlex author ID A5101515227. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
57
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: 3 papers · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 15

  1. Elevated circulating glycine levels are associated with reduced pancreatic cancer risk: A prospective cohort study based on the UK biobank. Co-author DOI 10.1016/j.pan.2025.12.015↗
  2. Prevalence, clinicopathological features, and prognosis of diabetes in pancreatic cancer: A single-center retrospective cohort study of 1620 patients. Co-author DOI 10.1016/j.pan.2025.11.004↗
  3. Treatment options in patients with pancreatic cancer: A 10-year multicenter epidemiological investigation in China. Co-author DOI 10.4251/wjgo.v17.i8.106447↗
  4. Overexpression of ZNF488 supports pancreatic cancer cell proliferation and tumorigenesis through inhibition of ferroptosis via regulating SCD1-mediated unsatur… Co-author DOI 10.1186/s13062-023-00421-6↗
  5. Subcellular localization of nucleolar protein 14 and its proliferative function mediated by miR-17-5p and E2F4 in pancreatic cancer. Last author DOI 10.18632/aging.204915↗
  6. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Co-author DOI 10.1016/j.jncc.2022.08.006↗
  7. Expression, Prognostic Value, and Functional Mechanism of the KDM5 Family in Pancreatic Cancer. Last author DOI 10.3389/fcell.2022.887385↗
  8. Prognostic Value, Immune Signature, and Molecular Mechanisms of the PHLDA Family in Pancreatic Adenocarcinoma. Last author DOI 10.3390/ijms231810316↗
  9. Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer. Last author DOI 10.1016/j.canlet.2021.08.029↗
  10. Over-expression of ANP32E is associated with poor prognosis of pancreatic cancer and promotes cell proliferation and migration through regulating β-catenin. Last author DOI 10.1186/s12885-020-07556-z↗
  11. First-line chemotherapy regimens for locally advanced and metastatic pancreatic adenocarcinoma: a Bayesian analysis. Last author DOI 10.2147/cmar.s162980↗
  12. Systemic Chemotherapy as First-line Treatment for Metastatic Pancreatic Adenocarcinoma: A Bayesian Analysis. Last author DOI 10.2169/internalmedicine.1114-18↗
  13. Clinicopathologic characteristics, laboratory parameters, treatment protocols, and outcomes of pancreatic cancer: a retrospective cohort study of 1433 patients… Last author DOI 10.7717/peerj.4893↗
  14. Effects of alcohol drinking and smoking on pancreatic ductal adenocarcinoma mortality: A retrospective cohort study consisting of 1783 patients. First author DOI 10.1038/s41598-017-08794-1↗
  15. Identification of genomic alterations in pancreatic cancer using array-based comparative genomic hybridization. Co-author DOI 10.1371/journal.pone.0114616↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongxing Du · 6 shared papers, 2021–2026 · strength 1.39
  2. Zongting Gu · 5 shared papers, 2020–2023 · strength 0.91
  3. Shuisheng Zhang · 6 shared papers, 2017–2025 · strength 0.74
  4. Xu Che · 4 shared papers, 2014–2026 · strength 0.68
  5. Xiaohao Zheng · 3 shared papers, 2022–2023 · strength 0.61
  6. Yunjie Duan · 3 shared papers, 2022–2023 · strength 0.61
  7. Jianwei Zhang · 6 shared papers, 2017–2023 · strength 0.59
  8. Shuai Xiang · 2 shared papers, 2025–2026 · strength 0.59
  9. Yunlong Li · 2 shared papers, 2025–2026 · strength 0.59
  10. Shunda Wang · 2 shared papers, 2023–2025 · strength 0.43
  11. Yingtai Chen · 4 shared papers, 2017–2018 · strength 0.31
  12. Hu Ren · 2 shared papers, 2020–2023 · strength 0.28
  13. Wanyi Sun · 1 shared paper, 2025 · strength 0.25
  14. Renyi Qin · 1 shared paper, 2025 · strength 0.25
  15. Shengping Li · 1 shared paper, 2025 · strength 0.25
  16. Rufu Chen · 1 shared paper, 2025 · strength 0.25
  17. Jin‐Hu Fan · 1 shared paper, 2025 · strength 0.25
  18. Yefeng Yin · 1 shared paper, 2023 · strength 0.20
  19. Xueping Zhao · 1 shared paper, 2021 · strength 0.19
  20. Qifeng Xiao · 1 shared paper, 2023 · strength 0.17
  21. Dan Li · 1 shared paper, 2023 · strength 0.17
  22. Jin Peng He · 1 shared paper, 2020 · strength 0.11
  23. Guotong Qiu · 1 shared paper, 2020 · strength 0.11
  24. Feng Jiao · 1 shared paper, 2022 · strength 0.09
  25. Zheng Wang · 1 shared paper, 2022 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.